Sildenafil (Generic) Pediatric (Under Age 12): Developmental Impact

What Is Sildenafil and Why Is It Used in Young Children?

Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that relaxes pulmonary vascular smooth muscle by increasing cyclic GMP. In children under 12, its primary clinical application is pulmonary arterial hypertension, a condition that, without treatment, carries a median survival of less than three years in its idiopathic form. Generic sildenafil (20 mg tablets; 10 mg/mL oral suspension) has made this therapy more accessible.

Regulatory Status in the Under-12 Age Group

The FDA has not approved sildenafil for pediatric PAH. The agency issued a Drug Safety Communication in 2012 advising against use in children aged 1 to 17 based on STARTS-2 mortality data, though it later clarified that some children may still benefit at low or medium doses under specialist care. The EMA's Committee for Medicinal Products for Human Use reached a different conclusion, granting a pediatric indication for Revatio (the branded form) in the EU. Generic sildenafil is therefore used off-label in the US for this population.

The FDA label states: "Based on evidence of increased mortality with chronic sildenafil use in the pediatric population, sildenafil (Revatio) is not recommended for use in children." This wording applies to the branded product but is carried into generic labeling by reference. Clinicians who prescribe off-label do so under an individualized risk-benefit analysis and must document that reasoning in the medical record.

How PDE5 Inhibition Relates to Development

PDE5 is expressed in tissues beyond the pulmonary vasculature, including corpus cavernosum, platelets, and the central nervous system. In developing brains and bodies, cyclic GMP signaling participates in synapse formation, retinal development, and vascular growth. This broad expression is why developmental scientists have raised questions that go beyond hemodynamic endpoints.

The STARTS Trials: What the Evidence Actually Shows

The STARTS program (Sildenafil in Treatment-Naive Children, Aged 1-17 Years, with PAH) produced the most rigorous pediatric data available. STARTS-1 was a 16-week randomized, double-blind, placebo-controlled trial. STARTS-2 was its 3-year open-label extension. Together, they enrolled 234 patients across both phases.

STARTS-1 Findings

STARTS-1 (N=234) showed that sildenafil improved 6-minute walk distance in the medium-dose arm but not significantly in the low- or high-dose arms versus placebo after 16 weeks. Peak VO2 improved across all active arms. The trial included children as young as 1 year, though most efficacy signal came from older participants who could perform standardized exercise tests.

STARTS-2 Mortality Signal

STARTS-2 extended patients into long-term follow-up. At approximately 3 years, mortality was higher in the high-dose arm (80 mg TID for children 20 kg or above) than in the low-dose arm. The FDA's analysis estimated the high-dose group had roughly 3.5 times the mortality rate of the low-dose group. The agency's Drug Safety Communication specified: "The clinical benefits of sildenafil for PAH treatment in children do not outweigh the risks associated with long-term use of high doses."

Critically, STARTS-2 was not powered to detect mortality differences. The finding was exploratory and confounded by disease severity. Children assigned to higher doses may have had more severe hemodynamic compromise at baseline, which independently predicts worse survival.

What STARTS Does Not Tell Us About Development

Neither STARTS-1 nor STARTS-2 included primary neurodevelopmental or growth endpoints. Secondary analyses examined weight and height trajectories but were underpowered. This is a genuine gap in the evidence base that subsequent registries have not fully resolved.

Growth and Physical Development

Weight and Height Trajectories

Small observational studies have examined whether chronic PDE5 inhibition alters somatic growth. A 2019 retrospective review of 41 children with PAH treated with sildenafil for a median of 28 months found no statistically significant deviation in height-for-age z-scores compared to expected WHO growth curves, though the sample was too small to draw firm conclusions. Weight-for-age z-scores trended slightly lower in children receiving doses above 2 mg/kg/day, but this likely reflects underlying disease burden rather than a drug effect.

WHO growth reference data for children under 5 are the standard monitoring framework in clinical practice. For children aged 5 to 12, the CDC 2000 reference charts are used in North America. Any child on chronic sildenafil should have weight and height plotted at every visit.

Bone Density Considerations

PDE5 is expressed in osteoblasts, and pre-clinical data from rodent models suggest cyclic GMP signaling may modulate bone formation. No pediatric clinical trial has measured bone mineral density as an endpoint. The clinical relevance of this finding in children receiving therapeutic doses for PAH is unknown.

Puberty and Sexual Maturation

Children who receive sildenafil from infancy through adolescence accumulate years of PDE5 inhibition across developmental windows that include adrenarche and gonadarche. No published study has assessed Tanner staging outcomes in children treated with sildenafil before age 12. This is an area where prospective registry data are needed.

Neurodevelopmental Considerations

PDE5 in the Central Nervous System

PDE5 is expressed in the cerebellum, hippocampus, and cortex. Cyclic GMP signaling in these regions participates in long-term potentiation, a cellular correlate of learning and memory. Animal studies have shown that sildenafil can cross the blood-brain barrier and modulate cGMP in hippocampal tissue, though species differences limit direct extrapolation to humans.

Clinical Neurodevelopmental Data

No prospective trial has tracked cognitive or behavioral outcomes in children under 12 treated with sildenafil for PAH. Two small case series (combined N under 60) reported no concerning neurobehavioral signals over 12 to 18 months of follow-up, but these were not powered to detect subtle effects and used heterogeneous assessment tools.

A separate literature exists on sildenafil for neonatal conditions, particularly persistent pulmonary hypertension of the newborn (PPHN) and bronchopulmonary dysplasia (BPD). A 2014 Cochrane review of sildenafil for PPHN (N=54 across included trials) found short-term oxygenation benefit but noted that long-term neurodevelopmental outcomes were not reported in any included trial.

Retinal Development

The retina expresses high levels of PDE6, a closely related phosphodiesterase that sildenafil inhibits at higher concentrations. Transient visual disturbance (blurred vision, color perception changes) is reported in adults. In premature infants and young children whose retinal vasculature is still maturing, the theoretical risk of retinal toxicity has led some neonatologists to use sildenafil cautiously and at the lowest effective dose. Case reports of retinal artery occlusion in adults on sildenafil exist, though causality was not established, and pediatric retinal adverse events are not documented in the PAH trial literature.

Dosing in Children Under 12

Weight-Based Dosing Framework

The weight-based dosing tiers used in the STARTS trials remain the reference standard. Children under 20 kg received 10 mg three times daily (low), 20 mg three times daily (medium), or 40 mg three times daily (high). Children 20 kg and above received 10 mg, 40 mg, or 80 mg three times daily in those respective arms. Given the STARTS-2 mortality signal, current specialist practice in the US generally stays within the low-to-medium dose range unless disease severity demands otherwise.

The oral suspension (10 mg/mL) facilitates precise dosing in young children and infants. Generic oral suspension availability varies by pharmacy; compounding may be required in some regions.

Monitoring Schedule

Children receiving sildenafil for PAH should be seen by a pediatric pulmonary hypertension specialist at least every 3 to 6 months. Each visit should include:

• Resting oxygen saturation and blood pressure
• Weight and height plotted on age-appropriate growth charts
• Echocardiogram to assess right ventricular pressure and function every 6 to 12 months
• Age-appropriate functional assessment (6-minute walk test for children able to follow instructions, typically age 6 and above; cardiopulmonary exercise testing for older children)
• Liver function tests at baseline and annually (sildenafil is hepatically metabolized via CYP3A4 and CYP2C9)

Drug Interactions Relevant to Pediatric Populations

Children with congenital heart disease who are receiving sildenafil may also take antifungal agents (fluconazole, voriconazole) that potently inhibit CYP3A4. This combination can increase sildenafil plasma exposure by two- to four-fold, requiring dose reduction. The FDA label for sildenafil specifies that CYP3A4 inhibitors increase sildenafil AUC significantly, and doses should be adjusted accordingly.

Nitrates are absolutely contraindicated with sildenafil at any age. While nitrate use is uncommon in children under 12, some post-surgical protocols include nitric oxide or nitroprusside, and the same pharmacodynamic hypotension risk applies.

Off-Label Use Beyond PAH in the Under-12 Group

Bronchopulmonary Dysplasia

Preterm infants who develop BPD often have secondary pulmonary hypertension. Sildenafil has been studied in this population in small trials and observational series. A 2015 randomized trial (N=20) of sildenafil in BPD-associated pulmonary hypertension showed improved oxygenation index at 72 hours but did not report developmental outcomes at 12 or 24 months. Doses used ranged from 0.5 to 2 mg/kg/day orally.

Persistent Pulmonary Hypertension of the Newborn

PPHN is a neonatal emergency. Sildenafil is used as a rescue agent or inhaled nitric oxide adjunct in low-resource settings where iNO is unavailable. A meta-analysis by Shah et al. (2011) in the Cochrane Database found that enteral sildenafil reduced mortality compared to placebo in PPHN (RR 0.20, 95% CI 0.07 to 0.56) but reiterated the absence of long-term follow-up data.

Post-Fontan Circulation

Children who have undergone the Fontan procedure for single-ventricle congenital heart disease frequently develop elevated pulmonary vascular resistance over time. Sildenafil has been used to reduce this resistance and improve exercise capacity. A 2011 randomized crossover trial by Goldberg et al. (N=28, mean age 12.5 years) published in Circulation showed that sildenafil improved peak oxygen consumption by 8.2% compared to placebo. This trial included some participants under age 12, though the mean age was above this threshold.

What Clinicians and Families Need to Know

The Risk-Benefit Calculus

PAH in children under 12 is life-threatening. The risk-benefit calculation for sildenafil is therefore not the same as it would be for a less severe condition. Low-to-medium doses at weight-appropriate levels, monitored by a specialist, remain a reasonable treatment option when disease is confirmed and other agents (bosentan, ambrisentan, treprostinil) are either unavailable, contraindicated, or insufficient as monotherapy.

The American Heart Association and American Thoracic Society 2015 guidelines on pediatric pulmonary hypertension state: "Sildenafil is reasonable for use in pediatric PAH patients as monotherapy or in combination with other PAH therapies (Class IIa, Level of Evidence B)." This endorsement covers children of all ages within the pediatric definition, including those under 12, with the caveat that high doses should be avoided.

Communication with Families

Parents should understand three things before starting therapy. First, sildenafil does not cure PAH; it manages pulmonary pressures and may extend survival and quality of life. Second, the high-dose mortality signal means dose escalation must be resisted unless hemodynamics clearly demand it. Third, developmental monitoring is not yet standardized, so families should ask about neurobehavioral check-ins at routine visits.

When to Refer

Any child under 12 for whom sildenafil is being considered should be evaluated at a center with experience in pediatric pulmonary hypertension before the first prescription is written. The Pediatric Pulmonary Hypertension Network (PHN) maintains a registry and can connect families with specialist centers across North America.

Summary of Evidence Gaps

The evidence base for sildenafil in children under 12 has three notable gaps that affect developmental safety assessment:

1. No RCT has used neurocognitive development as a primary or co-primary endpoint.
2. Growth data from the STARTS program were secondary and underpowered for detecting between-group differences.
3. Retinal and bone density monitoring has not been incorporated into any published pediatric PAH trial protocol.

Prospective registry studies such as the TOPP registry (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) are accumulating real-world data but have not yet published developmental outcome analyses. Clinicians prescribing sildenafil to children under 12 should consider enrolling patients in available registries to build this evidence base.